KM602

N/A

Report date: 2023/03/30 14:03:29

Base Information

Drug NameKM602
Drug Alias NameCD80-Fc fusion proteinKM602KM-602XZP-KM602
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed death-ligand 1 blockers
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Programmed death-ligand 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXuanzhu (HK) Biopharmaceutical Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A